KR100554816B1 - 비결정질 넬피나비르 메실레이트의 약학 제형 - Google Patents

비결정질 넬피나비르 메실레이트의 약학 제형 Download PDF

Info

Publication number
KR100554816B1
KR100554816B1 KR1020037014234A KR20037014234A KR100554816B1 KR 100554816 B1 KR100554816 B1 KR 100554816B1 KR 1020037014234 A KR1020037014234 A KR 1020037014234A KR 20037014234 A KR20037014234 A KR 20037014234A KR 100554816 B1 KR100554816 B1 KR 100554816B1
Authority
KR
South Korea
Prior art keywords
mesylate
nelfinavir
copolymer
nelfinavir mesylate
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037014234A
Other languages
English (en)
Korean (ko)
Other versions
KR20040007523A (ko
Inventor
인펠드마틴하워드
푸아프래딧원타니
샤나브닛하르고빈다스
창린
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20040007523A publication Critical patent/KR20040007523A/ko
Application granted granted Critical
Publication of KR100554816B1 publication Critical patent/KR100554816B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020037014234A 2001-05-03 2002-04-29 비결정질 넬피나비르 메실레이트의 약학 제형 Expired - Fee Related KR100554816B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03
US60/288,410 2001-05-03
PCT/EP2002/004711 WO2002089835A2 (en) 2001-05-03 2002-04-29 Pharmaceutical dosage form of amorphous nelfinavir mesylate

Publications (2)

Publication Number Publication Date
KR20040007523A KR20040007523A (ko) 2004-01-24
KR100554816B1 true KR100554816B1 (ko) 2006-02-22

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037014234A Expired - Fee Related KR100554816B1 (ko) 2001-05-03 2002-04-29 비결정질 넬피나비르 메실레이트의 약학 제형

Country Status (36)

Country Link
US (1) US7014866B2 (enExample)
EP (1) EP1390063B1 (enExample)
JP (1) JP4101661B2 (enExample)
KR (1) KR100554816B1 (enExample)
CN (1) CN1255185C (enExample)
AR (1) AR034320A1 (enExample)
AT (1) ATE282428T1 (enExample)
BG (1) BG108311A (enExample)
BR (1) BR0209325A (enExample)
CA (1) CA2444116C (enExample)
CZ (1) CZ20033211A3 (enExample)
DE (1) DE60201988T2 (enExample)
EA (1) EA006627B1 (enExample)
EC (1) ECSP034827A (enExample)
ES (1) ES2231717T3 (enExample)
GE (1) GEP20053466B (enExample)
GT (1) GT200200079A (enExample)
HR (1) HRP20030873B1 (enExample)
HU (1) HU229938B1 (enExample)
IL (2) IL158306A0 (enExample)
IS (1) IS7010A (enExample)
JO (1) JO2401B1 (enExample)
MA (1) MA27018A1 (enExample)
MX (1) MXPA03009971A (enExample)
MY (1) MY128509A (enExample)
NO (1) NO20034689D0 (enExample)
NZ (1) NZ528689A (enExample)
PA (1) PA8544501A1 (enExample)
PE (1) PE20021159A1 (enExample)
PL (1) PL366998A1 (enExample)
PT (1) PT1390063E (enExample)
RS (1) RS83503A (enExample)
SK (1) SK14572003A3 (enExample)
TW (1) TWI234461B (enExample)
UA (1) UA76463C2 (enExample)
WO (1) WO2002089835A2 (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
EP1652525A4 (en) * 2003-07-15 2008-10-01 Arigen Inc ANTI-CORONAVIRUS MEDICINE
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
WO2006060711A2 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
WO2007039420A1 (en) * 2005-09-23 2007-04-12 F. Hoffmann-La Roche Ag Novel dosage formulation
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
ES2350497T3 (es) * 2005-12-14 2011-01-24 F. Hoffmann-La Roche Ag Formulación de profármacos para el vhc.
CL2007002331A1 (es) * 2006-08-10 2008-04-18 Cipla Ltd Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih.
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008131259A1 (en) * 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
US8567657B2 (en) * 2007-04-30 2013-10-29 Mtj Consulting Services Inc. Coiled tubing with retainer for conduit
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
ES2401892T3 (es) 2007-05-01 2013-04-25 Concert Pharmaceuticals Inc. Compuestos morfinanos
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
EP3093290B1 (en) 2007-05-01 2018-01-24 Concert Pharmaceuticals Inc. Morphinan compounds
SI2003120T1 (sl) 2007-06-12 2010-03-31 Concert Pharmaceuticals Inc Azapeptidni derivati kot inhibitorji hiv proteaze
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
MX2010004222A (es) * 2007-10-19 2010-09-14 Purdue Research Foundation Formulaciones solidas de compuestos cristalinos.
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
EP2265334A2 (en) 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
ES2750825T3 (es) 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
WO2010062690A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
HUE028956T2 (en) 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
WO2010053550A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US20130084335A1 (en) 2010-06-14 2013-04-04 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828251A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals, Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
ME03652B (me) 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
AU2013208109A1 (en) 2012-01-09 2014-08-14 Anchor Therapeutics, Inc. APJ receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
SMT202500302T1 (it) 2012-06-15 2025-09-12 Sun Pharmaceutical Industries Inc Derivati deuterati del ruxolitinib
EP2885267B1 (en) 2012-07-12 2018-09-05 Concert Pharmaceuticals, Inc. Deuterated idebenone
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
JP2016503798A (ja) 2012-12-20 2016-02-08 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化ａｌｋ阻害剤
ES2700989T3 (es) 2012-12-21 2019-02-20 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
JP2016512831A (ja) 2013-03-15 2016-05-09 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたパルボシクリブ
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
CA2981791A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
WO2015188073A1 (en) 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
US20180243289A1 (en) 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
EP3352757B1 (en) 2015-09-21 2023-08-16 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
BR112018011784A2 (pt) 2015-12-09 2018-12-04 Res Triangle Inst agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
AU2017261286B2 (en) 2016-05-04 2023-03-23 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
ES2925277T3 (es) 2016-07-04 2022-10-14 Avanir Pharmaceuticals Inc Métodos para la síntesis de dextrometorfano deuterado
JP7178341B2 (ja) 2016-08-01 2022-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド タンパク質およびペプチドの送達のための粒子
CA3036382A1 (en) 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
ES3036483T3 (en) 2017-02-28 2025-09-19 Mayo Found Medical Education & Res Combinations for use in the treatment of cancer
WO2018213609A1 (en) 2017-05-17 2018-11-22 Ausubel Frederick M Antibiotic compounds
PH12019502544B1 (en) 2017-05-19 2023-07-26 Superb Wisdom Ltd Derivatives of resiquimod
JP7518765B2 (ja) 2017-11-22 2024-07-18 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
SG11202110533RA (en) 2019-04-10 2021-10-28 Mayo Found Medical Education & Res Methods and materials for gender-dependent treatment of cardiovascular dysfunction
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
EP4384173A1 (en) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN119255806A (zh) 2022-05-04 2025-01-03 太阳医药工业公司 用于用氘化jak抑制剂进行治疗的剂量方案

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
AU9496798A (en) * 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
DE60017444T2 (de) * 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
DE60201988D1 (de) 2004-12-23
ES2231717T3 (es) 2005-05-16
CA2444116C (en) 2009-01-20
BR0209325A (pt) 2004-07-20
CA2444116A1 (en) 2002-11-14
PT1390063E (pt) 2005-03-31
NO20034689L (no) 2003-10-20
GEP20053466B (en) 2005-02-25
US20030021840A1 (en) 2003-01-30
HU229938B1 (en) 2015-01-28
CZ20033211A3 (cs) 2004-09-15
TWI234461B (en) 2005-06-21
JP2004527569A (ja) 2004-09-09
WO2002089835A2 (en) 2002-11-14
NZ528689A (en) 2005-03-24
RS83503A (sr) 2006-10-27
UA76463C2 (en) 2006-08-15
SK14572003A3 (sk) 2004-12-01
IS7010A (is) 2003-10-30
HUP0401238A3 (en) 2012-09-28
IL158306A0 (en) 2004-05-12
WO2002089835A3 (en) 2003-05-01
HK1070285A1 (en) 2005-06-17
KR20040007523A (ko) 2004-01-24
PE20021159A1 (es) 2002-12-20
CN1547484A (zh) 2004-11-17
DE60201988T2 (de) 2005-12-15
MXPA03009971A (es) 2004-02-12
BG108311A (bg) 2004-12-30
ATE282428T1 (de) 2004-12-15
MA27018A1 (fr) 2004-12-20
JP4101661B2 (ja) 2008-06-18
NO20034689D0 (no) 2003-10-20
IL158306A (en) 2008-11-03
PA8544501A1 (es) 2002-11-18
PL366998A1 (en) 2005-02-07
EP1390063B1 (en) 2004-11-17
ECSP034827A (es) 2003-12-24
EP1390063A2 (en) 2004-02-25
HUP0401238A2 (hu) 2004-12-28
EA006627B1 (ru) 2006-02-24
GT200200079A (es) 2002-12-05
JO2401B1 (en) 2007-06-17
EA200301166A1 (ru) 2004-04-29
HRP20030873B1 (en) 2006-04-30
HRP20030873A2 (en) 2005-08-31
CN1255185C (zh) 2006-05-10
AR034320A1 (es) 2004-02-18
US7014866B2 (en) 2006-03-21
MY128509A (en) 2007-02-28

Similar Documents

Publication Publication Date Title
KR100554816B1 (ko) 비결정질 넬피나비르 메실레이트의 약학 제형
JP3162626B2 (ja) イルベサルタン含有医薬組成物
US7976869B2 (en) Fenofibrate tablets
US20160158203A1 (en) Methods of treatment with bioavailable compositions of metaxalone comprising nonvolatile liquids
JP2010280707A (ja) メシル酸サキナビル経口投与剤型
JP5318400B2 (ja) レボフロキサシン含有錠剤
AU2002319154B2 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP3470096B2 (ja) ニルバジピン含有易溶性固形製剤およびその製造法
RU2847102C1 (ru) Диспергируемые таблетированные композиции, содержащие долутегравир
AU2002319154A1 (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
Bhagwani Fomuation Development of an immediate release solid oral Dosage form for an Anti coagulant drug
JP2023522362A (ja) 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法
US20170273923A1 (en) Method of administering divalproex
HK1070285B (en) Pharmaceutical dosage form of amorphous nelfinavir mesylate
HK1184690A (en) Bioavailable solid dosage forms of metaxalone
HK1002384B (en) Pharmaceutical compositions containing irbesartan
JPWO1997040828A1 (ja) Ｓ１４５２の速放性錠剤

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130130

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20140129

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20150129

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180217

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180217

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000